N-GLYCOSYLATED HUMAN GROWTH HORMONE WITH PROLONGED CIRCULATORY HALF-LIFE
    21.
    发明申请
    N-GLYCOSYLATED HUMAN GROWTH HORMONE WITH PROLONGED CIRCULATORY HALF-LIFE 审中-公开
    N-糖化人体生长激素与延长循环半衰期

    公开(公告)号:US20110118183A1

    公开(公告)日:2011-05-19

    申请号:US13000266

    申请日:2009-06-26

    摘要: The present invention relates to novel human growth hormone (hGH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The hGH variants of the invention have a prolonged circulatory half-life and thus can be effectively used as a protein therapeutic for disease states that will benefit from increased levels of hGH. The process of obtaining the hGH variants is also encompassed by the invention.

    摘要翻译: 本发明涉及具有一个或多个N-聚糖的新型人生长激素(hGH)变体。 本发明的hGH变体包含氨基酸序列,其包含由野生型hGH中不存在的一种或多种突变产生的至少一种N-糖基化基序(N-X-S / T)。 本发明的hGH变体具有延长的循环半衰期,因此可以有效地用作将受益于增加的hGH水平的疾病状态的蛋白质治疗。 获得hGH变体的方法也包括在本发明中。

    ALBUMIN FUSION PROTEINS
    22.
    发明申请
    ALBUMIN FUSION PROTEINS 审中-公开
    ALBUMIN融合蛋白

    公开(公告)号:US20100249026A1

    公开(公告)日:2010-09-30

    申请号:US12784345

    申请日:2010-05-20

    CPC分类号: C12N15/62 C07K14/765

    摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

    摘要翻译: 本发明包括白蛋白融合蛋白。 编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中,载体含有这些核酸,用这些核酸载体转化的宿主细胞,以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法 酸,载体和/或宿主细胞。 另外,本发明包括包含白蛋白融合蛋白的药物组合物以及使用本发明的白蛋白融合蛋白来治疗,预防或改善疾病,病症或病症的方法。

    ORAL PHARMACEUTICAL PREPARATION FOR COLON-SPECIFIC DELIVERY
    24.
    发明申请
    ORAL PHARMACEUTICAL PREPARATION FOR COLON-SPECIFIC DELIVERY 审中-公开
    口腔特异性交付的口服药物制剂

    公开(公告)号:US20100209520A1

    公开(公告)日:2010-08-19

    申请号:US12450438

    申请日:2008-03-26

    申请人: Hiroyuki Kubo

    发明人: Hiroyuki Kubo

    摘要: The present invention relates to an oral pharmaceutical preparation having an excellent capability of delivering a drug to colon, more specifically an oral pharmaceutical preparation for delivering a drug to colon and comprising a core comprising at least a pharmaceutically acceptable vehicle, an inner layer covering said core and comprising said drug, an intermediate layer covering said inner layer and comprising a cationic polymer soluble or swellable at a pH of not more than 6.6, and an outer layer covering said intermediate layer and comprising an anionic polymer soluble at a pH of not less than 7.0.

    摘要翻译: 本发明涉及具有优异的向结肠递送药物的能力的口服药物制剂,更具体地,涉及用于将药物递送至结肠的口服药物制剂,其包含至少包含药学上可接受的载体的核心,覆盖所述核心的内层 并且包含所述药物,覆盖所述内层的中间层,并且包含在不超过6.6的pH下可溶或可溶胀的阳离子聚合物,以及覆盖所述中间层的外层,并且包含可溶于pH不小于 7.0。

    Unitary combinations of FSH and hCG
    25.
    发明申请
    Unitary combinations of FSH and hCG 有权
    FSH和hCG的单一组合

    公开(公告)号:US20080108571A1

    公开(公告)日:2008-05-08

    申请号:US11979265

    申请日:2007-10-31

    申请人: Marco Filicori

    发明人: Marco Filicori

    IPC分类号: A61K38/24 A61P5/06

    CPC分类号: A61K38/24 A61K2300/00

    摘要: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.

    摘要翻译: 一种新型的排卵诱导模式需要在治疗的所有阶段与FSH联合施用hCG,其中调整FSH与hCG的比例以优化排卵刺激并最小化并发症。 使用以各种FSH:hCG比率为特征的组合物使得从业者能够容易地调整治疗方案并适应不同的治疗目标以及个体患者对促性腺激素给药的反应。